Secondary mitral regurgitation (MR) can be a serious complication of heart failure — in a recent study, two-thirds of the people who were taking the maximum recommended doses of drugs for severe forms ...

Surgical repair decreased MR more than MitraClip ®. In 12-month follow-up, 20% of MitraClip patients required surgery for mitral dysfunction versus 2% in surgical patients. Both groups had ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter mitral valve repair improved clinical outcomes in patients with HF across all quartiles of mitral ...

Abbott Laboratories, Inc. ABT recently presented late-breaking data from the Landmark COAPT trial for MitraClip, demonstrating the long-term benefits of the device in patients fighting heart failure.

A study presented at the annual Heart Rhythm Society meeting in Boston found that Abbott's ($ABT) percutaneous MitraClip mitral valve repair device cut the number of ...

One-year mortality rates for patients with secondary mitral regurgitation (MR) treated with the next-generation MitraClip NTR and XTR systems (Abbott) as part of the real-world, global EXPAND registry ...

The US Food and Drug Administration (FDA) has expanded the indication for the MitraClip (Abbott) device to include patients with normal mitral valves who develop symptoms of heart failure and moderate ...

Treatment with Minimally Invasive Device Can Improve Quality of Life for Patients with Debilitating Mitral Valve Disease Who Are at Prohibitive Surgical Risk Abbott Park, Ill. — Abbott today announced ...

- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology - MitraClip is a first-of-its-kind ...

In 2016, medical device giant Abbott issued a recall for its MitraClip cardiac device — “a Class I recall, the most serious type,” the FDA said. “Use of this device may cause serious injuries or death ...

PARIS, May 25 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced new data from the landmark EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) trial ...

In 2013, the FDA approved an implantable device to treat leaky heart valves. Among its inventors was Mehmet Oz, the former television personality and former U.S. Senate candidate widely known as “Dr.